HCM: AI 评分 42/100 — AI 分析 (4月 2026)

HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies, primarily in oncology and immunology. The company operates both in Hong Kong and internationally, with a diverse pipeline of drug candidates targeting various cancers and immunological diseases.

Key Facts: Price: $13.37 AI Score: 42/100 Sector: Healthcare

公司概况

概要：

HUTCHMED (China) Limited, a biopharmaceutical company based in Hong Kong, specializes in developing and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. With a focus on oncology and immunology, the company boasts a diverse pipeline of drug candidates and strategic collaborations to drive growth in the global pharmaceutical market.

HCM是做什么的？

HUTCHMED (China) Limited, formerly known as Hutchison China MediTech Limited, was incorporated in 2000 and is headquartered in Central, Hong Kong. The company is dedicated to the discovery, development, and commercialization of innovative therapeutics, particularly in oncology and immunology. HUTCHMED operates through two segments: Oncology/Immunology and Other Ventures. Its pipeline includes several drug candidates targeting various cancers, such as colorectal cancer (CRC), non-small cell lung cancer (NSCLC), gastric cancer (GC), and neuroendocrine tumors (NET). Key products under development include Savolitinib, Fruquintinib, and Surufatinib. HUTCHMED has established strategic collaborations with major pharmaceutical companies, including AstraZeneca, Lilly, and BeiGene, to accelerate the development and commercialization of its drug candidates. These collaborations provide HUTCHMED with access to resources, expertise, and global markets. The company's focus on targeted therapies and immunotherapies positions it to address unmet medical needs in cancer and immunological diseases. HUTCHMED's commitment to innovation and strategic partnerships underscores its mission to improve patient outcomes and create value for shareholders. As of 2026, HUTCHMED employs 1,811 individuals.

HCM的投资论点是什么？

HUTCHMED (China) Limited presents a notable market position within the biopharmaceutical sector, driven by its focus on oncology and immunology. With a market capitalization of $2.52 billion and a profit margin of 77.5%, the company demonstrates strong financial performance. Key value drivers include the successful development and commercialization of its drug pipeline, particularly Fruquintinib and Savolitinib. Growth catalysts include potential regulatory approvals and expansion into new markets. However, potential may be worth researching risks such as clinical trial failures and competition from other pharmaceutical companies. The company's strategic collaborations and focus on innovative therapies position it for long-term growth.

HCM在哪个行业运营？

HUTCHMED (China) Limited operates in the competitive pharmaceutical industry, specifically within the specialty and generic drug manufacturing segment. The global oncology market is experiencing significant growth, driven by increasing cancer prevalence and advancements in targeted therapies and immunotherapies. HUTCHMED's focus on these areas positions it to capitalize on these trends. The company competes with other pharmaceutical companies developing similar treatments, including ADPT, BHC, CDTX, CPRX, and IDYA. Success in this industry requires innovation, strategic partnerships, and effective navigation of regulatory processes.

Drug Manufacturers - Specialty & Generic

Healthcare

HCM有哪些增长机遇？

Expansion of Fruquintinib into New Indications: Fruquintinib, an inhibitor for CRC, breast cancer, GC, EMC, NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors, represents a significant growth opportunity for HUTCHMED. Expanding its use into additional indications beyond CRC could substantially increase its market reach and revenue potential. The global market for cancer therapeutics is projected to reach $200 billion by 2028, providing a substantial addressable market.
Development and Commercialization of Savolitinib: Savolitinib, an inhibitor for NSCLC, papillary and renal cell carcinoma, CRC, and GC, is another key growth driver. Successful clinical trials and regulatory approvals for these indications could drive significant revenue growth. The NSCLC market alone is expected to reach $35 billion by 2027, offering a substantial opportunity for HUTCHMED.
Strategic Collaborations and Partnerships: HUTCHMED's existing collaborations with AstraZeneca, Lilly, and BeiGene provide access to resources, expertise, and global markets. Forming new strategic partnerships with other pharmaceutical companies could further accelerate drug development and commercialization efforts. These partnerships can also provide access to new technologies and therapeutic areas.
Expansion into New Geographic Markets: While HUTCHMED operates internationally, expanding its presence into new geographic markets, particularly in Europe and the United States, could drive significant growth. This expansion would require navigating regulatory processes and establishing commercial infrastructure, but the potential rewards are substantial. The global pharmaceutical market is expected to reach $1.5 trillion by 2026.
Advancement of Immunotherapy Pipeline: HUTCHMED is developing several immunotherapies for cancer and immunological diseases. Advancing these drug candidates through clinical trials and securing regulatory approvals could create new revenue streams and diversify the company's product portfolio. The immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other novel therapies.

Market capitalization of $2.52 billion reflects investor confidence in HUTCHMED's growth potential.
Profit margin of 77.5% indicates strong operational efficiency and profitability.
Gross margin of 8.9% demonstrates the company's ability to manage production costs effectively.
Beta of 0.51 suggests lower volatility compared to the overall market, making it a potentially stable investment.
Strategic collaborations with AstraZeneca and Lilly enhance HUTCHMED's drug development and commercialization capabilities.

HCM提供哪些产品和服务？

Discovers and develops targeted therapeutics for cancer and immunological diseases.
Commercializes innovative drugs in Hong Kong and internationally.
Focuses on oncology and immunology, addressing unmet medical needs.
Develops inhibitors for various cancers, including colorectal cancer and lung cancer.
Conducts clinical trials to evaluate the safety and efficacy of drug candidates.
Establishes strategic collaborations with major pharmaceutical companies.
Navigates regulatory approval processes to bring new drugs to market.

HCM如何赚钱？

Develops and patents novel therapeutic drugs.
Out-licenses or co-develops drugs with pharmaceutical partners.
Generates revenue from drug sales and royalties.
Invests in research and development to expand its drug pipeline.

Patients with cancer and immunological diseases.
Healthcare providers who prescribe HUTCHMED's drugs.
Pharmaceutical companies that partner with HUTCHMED.
Hospitals and clinics that use HUTCHMED's therapies.

Proprietary drug pipeline with patented compounds.
Strategic collaborations with major pharmaceutical companies.
Expertise in oncology and immunology drug development.
Established presence in the Chinese pharmaceutical market.

什么因素可能推动HCM股价上涨？

Upcoming: Regulatory approvals for Fruquintinib in new indications.
Upcoming: Clinical trial results for Savolitinib in NSCLC.
Ongoing: Expansion of strategic collaborations with pharmaceutical companies.
Ongoing: Advancement of immunotherapy pipeline through clinical trials.

HCM的主要风险是什么？

Potential: Clinical trial failures and regulatory setbacks.
Potential: Competition from other pharmaceutical companies.
Ongoing: Dependence on key partnerships for drug development and commercialization.
Ongoing: Changes in healthcare regulations and reimbursement policies.

HCM的核心优势是什么？

Strong pipeline of oncology and immunology drug candidates.
Strategic collaborations with major pharmaceutical companies.
Experienced management team with expertise in drug development.
Established presence in the Chinese pharmaceutical market.

HCM的劣势是什么？

Reliance on clinical trial success and regulatory approvals.
Competition from other pharmaceutical companies.
Dependence on key partnerships for drug development and commercialization.
Limited geographic diversification.

HCM有哪些机遇？

Expansion into new therapeutic areas and indications.
Growth in the global oncology and immunology markets.
Increased demand for targeted therapies and immunotherapies.
Potential for new strategic partnerships and collaborations.

HCM面临哪些威胁？

Clinical trial failures and regulatory setbacks.
Competition from generic drugs and biosimilars.
Changes in healthcare regulations and reimbursement policies.
Economic downturns and market volatility.

HCM的竞争对手是谁？

Adaptive Biotechnologies Corp — Focuses on immune-driven medicine. — (ADPT)
Bausch Health Companies Inc — Diversified pharmaceutical portfolio. — (BHC)
Cidara Therapeutics Inc — Develops anti-infectives. — (CDTX)
Catalent Inc — Provides drug development and manufacturing services. — (CPRX)
IDEAYA Biosciences Inc — Focuses on precision medicine oncology. — (IDYA)

Key Metrics

Price: $13.37 (-2.05%)
Market Cap: $2.41B
Volume: 98,987
MoonshotScore: 42/100

Company Profile

CEO: Chig Fung Cheng
Headquarters: Hong Kong, HK
Employees: 1,811
Founded: 2016

AI Insight

HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies. They operate in the Oncology/Immunology segment, developing treatments for various cancers and immunological diseases.

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does HUTCHMED (China) Limited do?

HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapeutics and immunotherapies for cancer and immunological diseases. The company operates primarily in the Oncology/Immunology segment, developing treatments for various cancers such as colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and gastric cancer (GC). HUTCHMED collaborates with major pharmaceutical companies to accelerate drug development and commercialization, aiming to address unmet medical needs and improve patient outcomes.

What do analysts say about HCM stock?

Analyst consensus on HCM stock is not available in the provided data. However, key valuation metrics such as market capitalization ($2.52 billion) and profit margin (77.5%) provide insights into the company's financial health. Growth considerations include the successful development and commercialization of its drug pipeline, as well as potential regulatory approvals and expansion into new markets. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions.

What are the main risks for HCM?

The main risks for HUTCHMED (China) Limited include clinical trial failures and regulatory setbacks, which could delay or prevent the approval of its drug candidates. Competition from other pharmaceutical companies developing similar treatments also poses a risk. Additionally, the company's dependence on key partnerships for drug development and commercialization could be a vulnerability. Changes in healthcare regulations and reimbursement policies could also impact the company's profitability and growth prospects.